Splenectomy for Massive splenomegaly: Long-term results and risks for mortality

Annals of Surgery

Volumn 258, Issue 6, 2013, Pages 1034-1039

  Taner, Timucin ^a   Nagorney, David M ^a   Tefferi, Ayalew ^b   Habermann, Thomas M ^b   Harmsen, William S ^a   Slettedahl, Seth W ^a   Donohue, John H ^a  

^a MAYO CLINIC   (United States)

^b Division of Hematology   (United States)

Author keywords

lymphoma; myeloid metaplasia; splenectomy; splenomegaly

Indexed keywords

ADULT; AGE; AGED; ANEMIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CRYOPRECIPITATE; DIAPHRAGM INJURY; ERYTHROCYTE; FEMALE; HEART INFARCTION; HUMAN; HYPOTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOID METAPLASIA; NONHODGKIN LYMPHOMA; OPERATION DURATION; ORGAN WEIGHT; PANCREAS FISTULA; PANCREAS INJURY; PEROPERATIVE COMPLICATION; PLASMA TRANSFUSION; PNEUMONIA; PORTAL VEIN THROMBOSIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PRIORITY JOURNAL; REMISSION; REOPERATION; RISK FACTOR; SEPSIS; SEX DIFFERENCE; SHOCK; SPLENECTOMY; SPLENOMEGALY; STOMACH INJURY; SURGICAL INFECTION; SURVIVAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SPLENECTOMY; SPLENOMEGALY; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84888127944     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318278d1bf     Document Type: Article

References (17)

1. Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood. 2003;101:2464-2472.
2. Tefferi A, Mesa RA, Nagorney DM, et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226-2233.
3. Yoong Y, Kurtin PJ, Allmer C, et al. Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2001;42:1235-1241.
4. Royal Society of Medicine. Lancet. 1929;213:977-982.
5. Mesa RA, Nagorney DS, Schwager S, et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107:361-270.
6. Horowitz J, Smith JL, Weber TK, et al. Postoperative complications after splenectomy for hematologic malignancies. Ann Surg. 1996;223:290-296.
7. Nelson EW, Mone MC. Splenectomy in high-risk patients with splenomegaly. Am J Surg. 1999;178:581-586.
8. McAneny D, LaMorte WW, Scott TE, et al. Is splenectomy more dangerous for massive spleens? Am J Surg. 1998;175:102-107.
9. Loring LA, Panicek DM, Karpeh MS. Portal system thrombosis after splenectomy for neoplasm or chronic hematologic disorder: is routine surveillance imaging necessary? J Comput Assist Tomogr. 1998;22:856-860.
10. Mahon D, Rhodes M. Laparoscopic splenectomy: size matters. Ann R Coll Surg Engl. 2003;85:248-251.
11. Patel AG, Parker JE, Wallwork B, et al. Massive splenomegaly is associated with significant morbidity after laparoscopic splenectomy. Ann Surg. 2003;238:235-240.
12. Boddy AP, Mahon D, Rhodes M. Does open surgery continue to have a role in elective splenectomy? Surg Endosc. 2006;20:1094-1098.
13. Casaccia M, Torelli P, Pasa A, et al. Putative predictive parameters for the outcome of laparoscopic splenectomy: a multicenter analysis performed on the Italian Registry of Laparoscopic Surgery of the Spleen. Ann Surg. 2010;251:287-291.
14. Grahn SW, Alvarez J, III, Kirkwood K. Trends in laparoscopic splenectomy for massive splenomegaly. Arch Surg. 2006;141:755-761.
15. Koshenkov VP, Nemeth ZH, Carter MS. Laparoscopic splenectomy: outcome and efficacy for massive and supramassive spleens. Am J Surg. 2011;14:14.
16. Swanson TW, Meneghetti AT, Sampath S, et al. Hand-assisted laparoscopic splenectomy versus open splenectomy for massive splenomegaly: 20-year experience at a Canadian centre. Can J Surg. 2011;54:189-193.
17. Barosi G, Ambrosetti A, Buratti A, et al. Splenectomy for patientswithmyelofibrosis withmyeloidmetaplasia: pretreatment variables and outcome prediction. Leukemia. 1993;7:200-206.